| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -2.3 | -4.0 |
| Net income | -2.3 | -4.0 |
| EPS (diluted, $ a share) | $-0.17 | $-1.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, OTC: RVPH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Reviva Pharmaceuticals Holdings, Inc.: key numbers
- Share price
- $0.3000Close, Nov 16
- Market cap
- $3.93M
- Shares outstanding
- 13.11MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Reviva Pharmaceuticals Holdings, Inc.
All →Reviva Pharmaceuticals Holdings Financial Results
Reviva Pharmaceuticals reported a net loss of $2.3 million for the third quarter of 2026, an improvement from a $4.0 million loss in the prior year period. The company is awaiting FDA feedback in Q4 2026 regarding a new formulation of brilaroxazine for its Phase 3 RECOVER-2 trial in schizophrenia. Reviva also noted it has filed a new composition of matter patent application that could extend protection for brilaroxazine through 2046.
- Term
- Q3 2026
“Our near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva
“We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva